Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

(RTTNews) - Biogen Inc. (BIIB) said that the European Commission has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Treatment goals for Friedreich ataxia include symptom management, slowing disease progression, and enhancing quality of life through multidisciplinary care. Supportive therapies address comorbidities ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...

Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12 ...

Moreover, Friedreich's ataxia treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Friedreich's ataxia market growth may be offset by ...

Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...

A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings. A key opinion ...